What the FDA labels say about taking them together
Cyclobenzaprine and oxycodone
Oxycodone's FDA label of May 6, 2026 names cyclobenzaprine in its drug interactions section; the cyclobenzaprine labels PlainMeds reads (3) do not name oxycodone. The oxycodone label: “The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.”
Check it at the source: the cyclobenzaprine FDA label on DailyMed (effective February 21, 2025, Jubilant Cadista Pharmaceuticals Inc.); the oxycodone FDA label on DailyMed (effective May 6, 2026, Rhodes Pharmaceuticals LLC).
What does the cyclobenzaprine label say about oxycodone?
Cyclobenzaprine's label (effective February 21, 2025) and its 2 other brand-application labels do not name oxycodone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Cyclobenzaprine Hydrochloride), Jubilant Cadista Pharmaceuticals Inc., effective February 21, 2025 (SPL set 592871f6-0eb2-4624-9e10-bd8bf767c002), via openFDA; the full label on DailyMed
What does the oxycodone label say about cyclobenzaprine?
Oxycodone label, drug interactionsSerotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
Roxicodone label (SpecGx LLC, April 24, 2026), drug interactionsSerotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
Source: FDA drug label (Roxicodone, NDA021011), SpecGx LLC, effective April 24, 2026 (SPL set 5a8157d3-ba20-4abf-b0d4-6ad141b31d63), via openFDA
Source: FDA drug label (Oxaydo, NDA202080), Zyla Life Sciences US LLC, effective January 4, 2026 (SPL set cff0c64a-63f5-4b3c-909a-cdecf6755cbe), via openFDA
Source: FDA drug label (Oxycodone Hydrochloride), Rhodes Pharmaceuticals LLC, effective May 6, 2026 (SPL set a5162476-1217-41c0-bc7e-0a0f123f069f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclobenzaprine | Oxycodone | |
|---|---|---|
| Labeled for | Muscle spasms and spasticity, Nerve pain and fibromyalgia | Pain |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0171 per tablet 10 mg tablet | $0.0884 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once